Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic obstructive pulmonary disease (COPD) patient populations…
Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology's coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs)…